FridayMay 06, 2022 9:00 am

Cybin Inc.’s (NEO: CYBN) (NYSE American: CYBN) Proprietary CYB003 Set to Move Forward in First-in-Human Phase 1/2a Clinical Trial

Cybin has selected Clinilabs Drug Development Corporation as CRO for its Phase 1/2a clinical trial evaluating CYB003 for treating major depressive disorder (“MDD”) MDD impacts more than 264 million people worldwide, is a leading cause of mental disability worldwide Preclinical studies show CYB003 may have significant advantages over classic psilocybin In a significant step forward in the study of alternative treatments for major depressive disorder, Cybin (NEO: CYBN) (NYSE American: CYBN) is moving forward in its phase 1/2a clinical trial of its proprietary deuterated psilocybin, CYB003 (https://ibn.fm/VTjoI). Based on previous research, CYB003 has the potential to effectively treat MDD with significant…

Continue Reading

ThursdayMay 05, 2022 2:19 pm

Tesla CEO Elon Musk Believes Psychedelics Are Better Than Pharmaceutical Medications

Tesla CEO Elon Musk recently stated on Twitter that psychedelic substances and other plant-based drugs were effective as treatments for a number of mental health conditions. Musk has in the past smoked a joint during a livestream video. The tweet in question is an excerpt from a conversation between a pair of Twitter users, one of whom referred to a feature on the New York Times, which discussed Adderall. The other user replied to the tweet, noting that prescribed psychedelic drugs would soon replace selective serotonin reuptake inhibitors (SSRIs) and amphetamines, probably in the next decade. SSRIs are antidepressants commonly…

Continue Reading

WednesdayMay 04, 2022 3:40 pm

Studies Find Link Between ADHD, Fibromyalgia

Various studies have found a link between fibromyalgia and ADHD, with some urging clinicians to evaluate the presence of attention deficit hyperactivity disorder (ADHD) in individuals who have a history of fibromyalgia. ADHD is a condition characterized by persistent impulsivity, hyperactivity, impaired concentration and inattention, as well as disorganized behavior, anxiety and emotional instability. The CDC estimates that while more than 8% of children have been diagnosed with this condition thus far, less than 1% of adults have received the same consideration. Fibromyalgia is a chronic pain disorder linked to modified activity of the neurotransmitters involved in pain sensitivity, with…

Continue Reading

TuesdayMay 03, 2022 3:52 pm

Research Finds That Mushrooms May Have Their Own Language

New research has found that mushrooms have their own language that they use to talk to each other. The study, which was conducted by Professor Andrew Adamatzky of the University of the West of England, published its findings in the “Royal Society.” For their study, the researchers in Adamatzky’s laboratory focused on four different fungi: caterpillar, ghost, split gill and enoki fungi. They monitored the electrical signals that fungi send to each other via the underground tubes that connect them in a fungal colony, known as hyphae. The researchers then analyzed these signals, discovering that the signals pulsed in patterns…

Continue Reading

TuesdayMay 03, 2022 9:00 am

Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) Set to Present Update on its Psychedelic Wellness Ecosystem at Las Vegas MicroCap Event

Delic Holdings Corp was founded four years ago, devoted to making psychedelic drug therapies available to patients with hard-to-treat mental and emotional conditions  The company’s research arm has received authorization in Canada to work with substances such as psilocybin, MDMA (Ecstasy), LSD, DMT (Dimitri), mescaline and 2C-B In the United States, the company operates the country’s largest chain of ketamine (anesthesia-related medication) clinics for wellness therapies Delic Co-founder and CEO Matt Stang will continue his outreach to investors and other potential sources of industry financing when he presents an overview of the company’s operations and its outlook for the coming…

Continue Reading

MondayMay 02, 2022 2:29 pm

Experts Convene in Seattle to Discuss Future of Psychedelics

Psychedelics are increasingly being studied as therapies for various mental health conditions, including treatment-resistant depression. Last week, advocacy workers, doctors, researchers and farmers gathered in South Lake Union to discuss how psychedelics could be used in the treatment of addiction and substance-use disorders. So far, Seattle is the biggest city in the United States to decriminalize psilocybin, which is the active ingredient of hallucinogenic mushrooms. This gathering marked the launch of a new research hub devoted to the use of psychedelics in treating addiction and substance-use disorders. The chair of the Department of Behavioral Sciences and Psychiatry at the School…

Continue Reading

FridayApr 29, 2022 12:48 pm

Vancouver Island University to Expand Psychedelic Mental Healthcare Program

Vancouver Island University has plans to expand its psychedelic-assisted therapy program by providing a graduate certificate program in the use of psychedelic drugs, such as psilocybin, in mental health care. This will make it the pioneer accredited university in Canada to do so. This program was developed by Professor Pamela Kryskow and Shannon Dames, a nursing professor at the institution; both individuals have years of experience with a separate program that uses psychedelic-assisted therapy to manage end-of-life distress. Dames’ interest in these therapies arose after her experience using psychedelics to process her own childhood trauma. Dames revealed that she had…

Continue Reading

FridayApr 29, 2022 9:00 am

Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) Driving the Psychedelic Conversation Forward Through Education, Research, and Service Delivery

Delic is committed to bringing science-backed benefits to as many people as possible while also changing the narrative around psychedelics It seeks to achieve this through education, products and services, and research on psychedelics  So far, LSD and psilocybin have proven to reduce end of life (“EOL”) anxiety for terminally ill patients Delic recognizes the potential of psychedelics and their application in therapeutics, hence its investment in research, civic education, and service delivery in this sector For many years, psychedelic drugs were frowned upon by society. This, along with psychedelics’ widespread popularity as recreational drugs in the 1960s and 70s,…

Continue Reading

ThursdayApr 28, 2022 2:25 pm

Advocates Urge Use of Alternative Treatments to Curb Veteran Suicides

Recently released federal data shows that in the state of Texas, approximately 10 veterans are taking their lives every week. Various veterans’ organizations and advocates are calling for the state government to find alternative ways, such as psychedelics, to tackle this issue. In an interview, Navy veteran Marcus Capone revealed that he’d been diagnosed with depression after leaving the military. Capone, who is cofounder of the VETS not-for-profit organization, explained that he turned to psychedelic drugs after current treatments proved to be ineffective. The VETS nonprofit was established to allocate funding for psychedelic therapy and help run as well as…

Continue Reading

ThursdayApr 28, 2022 9:30 am

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Releases Preclinical Data from CYB004 Study Showing Significant Advantages

Earlier studies show that CYB004 via inhalation may solve existing challenges and support a clinical path forward for this important therapeutic Cybin is currently developing CYB004 for the treatment of anxiety disorders The new chemical entity is covered by a patent issued earlier this year Cybin (NEO: CYBN) (NYSE American: CYBN) has released data from a pharmacokinetic study focused on evaluating CYB004, the company’s proprietary deuterated dimethyltryptamine (“DMT”) molecule (https://ibn.fm/nyCj8). The study analyzed delivery methods of CYB004, and showed initial data indicates significant advantages over Intravenous (“IV”) and Inhaled DMT. "In many studies, DMT has shown to be a promising and…

Continue Reading

PsychedelicNewsWire Currently Accepts

Bitcoin

Bitcoin

Bitcoin Cash

Bitcoin Cash

Doge Coin

Dogecoin

Ethereum

Ethereum

Litecoin

Litecoin

USD Coin

USD Coin

Contact us: 415.949.5050